Apimeds faces hostile takeover attempt by Inscobee; company says consent void, files emergency action

Apimeds Pharmaceuticals US, Inc.

On March 20, 2026, Inscobee and Apimeds Korea claimed to remove all four directors and CEO/CFO via written consent.
Company states the consent violates the irrevocable proxy granted under the Support Agreement from Dec 1, 2025.
Inscobee used 6,416,365 shares subject to proxy; without those, consent lacks majority under Delaware law.
Company will file emergency action in Delaware Court of Chancery under 8 Del. C. § 225 to void consent.
Purported new board approved business expansions without authorization; company disputes them.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Apimeds Pharmaceuticals US, Inc.: Attempted amendment to the Amended and Restated Bylaws via stockholder written consent, which the company asserts is invalid.

Change: bylaw amendment

Exact text from the filing

Because the Stockholder Consent is invalid, the amendment to the Amended and Restated Bylaws of the Company made in connection with the Stockholder Consent is invalid.

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

Apimeds Pharmaceuticals US, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-034786

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.